Current Hypertension Reports

, 16:498 | Cite as

Recent Insights on Circulating Catecholamines in Hypertension

  • Quang V. TonEmail author
  • Stephen R. HammesEmail author
Secondary Hypertension: Nervous System Mechanisms (J Bisognano, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Secondary Hypertension: Nervous System Mechanisms


Pheochromocytomas are neuroendocrine tumors that commonly lead to excess catecholamine secretion, resulting in elevated blood pressure. In addition to potentiating vasoconstriction, catecholamines promote endothelial dysfunction, as evidenced by elevated markers of endothelial dysfunction, ADMA and sVCAM-1, in patients with pheochromcytoma. Importantly, catecholamine-induced endothelial dysfunction and hypertension may not only be due to catecholamine production by neuroendocrine tumors, as vascular endothelial cells have now been demonstrated to synthesize and secrete catecholamines. This local vascular catecholamine release appears to be triggered by hypoxia. In fact, chronic intermittent hypoxia both in vitro and in vivo leads to stabilization of hypoxic-inducible factors that increase gene expression of catecholamine-synthesizing enzymes. In an effort to target catecholamines as a means of treating hypertension, novel therapeutic options are being explored, including the generation of pharmacophores that mimic the suppressive effects of catestatin on catecholamine release as well as the use of renalase enhancers to increase catecholamine metabolism.


Catecholamines Hypertension Endothelium Hypoxia Apnea Hypoxia-inducible factor Pheochromocytoma Metanephrines Chromogranin A Catestatin Renalase 


Compliance with Ethics Guidelines

Conflict of Interest

Quang V. Ton and Stephen R. Hammes declare no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance, •• Of major importance

  1. 1.
    Calhoun DA et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008;51(6):1403–19.PubMedCrossRefGoogle Scholar
  2. 2.
    Stein PP, Black HR. A simplified diagnostic approach to pheochromocytoma. A review of the literature and report of one institution’s experience. Medicine (Baltimore). 1991;70(1):46–66.CrossRefGoogle Scholar
  3. 3.
    Nagatsu T, Levitt M, Udenfriend S, Udenfriend S. Tyrosine hydroxylase. The initial step in norepinephrine biosynthesis. J Biol Chem. 1964;239:2910–7.PubMedGoogle Scholar
  4. 4.
    Axelrod J, Weinshilboum R. Catecholamines. N Engl J Med. 1972;287(5):237–42.PubMedCrossRefGoogle Scholar
  5. 5.
    Kopin IJ. Monoamine oxidase and catecholamine metabolism. J Neural Transm Suppl. 1994;41:57–67.PubMedGoogle Scholar
  6. 6.
    Sumpio BE, Riley JT, Dardik A. Cells in focus: endothelial cell. Int J Biochem Cell Biol. 2002;34(12):1508–12.PubMedCrossRefGoogle Scholar
  7. 7.
    Iaccarino G et al. Beta(2)-adrenergic receptor gene delivery to the endothelium corrects impaired adrenergic vasorelaxation in hypertension. Circulation. 2002;106(3):349–55.PubMedCrossRefGoogle Scholar
  8. 8.
    Engler KL et al. Autocrine actions of macrophage-derived catecholamines on interleukin-1 beta. J Neuroimmunol. 2005;160(1–2):87–91.PubMedCrossRefGoogle Scholar
  9. 9.••
    Sorriento D et al. Endothelial cells are able to synthesize and release catecholamines both in vitro and in vivo. Hypertension. 2012;60(1):129–36. First report revealing that endothelial cells have the enzymes and machinery to synthesize and secrete catecholamines.PubMedCrossRefGoogle Scholar
  10. 10.
    Wilcken DE et al. Asymmetric dimethylarginine (ADMA) in vascular, renal and hepatic disease and the regulatory role of l-arginine on its metabolism. Mol Genet Metab. 2007;91(4):309–17. discussion 308.PubMedCrossRefGoogle Scholar
  11. 11.
    Boger RH et al. An endogenous inhibitor of nitric oxide synthase regulates endothelial adhesiveness for monocytes. J Am Coll Cardiol. 2000;36(7):2287–95.PubMedCrossRefGoogle Scholar
  12. 12.•
    Vasilev V et al. Asymmetric dimethylarginine (ADMA) and soluble vascular cell adhesion molecule 1(sVCAM-1) as circulating markers for endothelial dysfunction in patients with pheochromocytoma. Exp Clin Endocrinol Diabetes. 2013;121(9):551–5. This study showed elevated markers of endothelial cell dysfunction in association with pheochromocytoma and essential hypertension.PubMedCrossRefGoogle Scholar
  13. 13.
    Carlson JT et al. Augmented resting sympathetic activity in awake patients with obstructive sleep apnea. Chest. 1993;103(6):1763–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Marrone O et al. Catecholamines and blood pressure in obstructive sleep apnea syndrome. Chest. 1993;103(3):722–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Leuenberger U et al. Surges of muscle sympathetic nerve activity during obstructive apnea are linked to hypoxemia. J Appl Physiol. 1995;79(2):581–8.PubMedGoogle Scholar
  16. 16.
    Silverberg DS, Oksenberg A, Iaina A. Sleep-related breathing disorders as a major cause of essential hypertension: fact or fiction? Curr Opin Nephrol Hypertens. 1998;7(4):353–7.PubMedCrossRefGoogle Scholar
  17. 17.
    Imadojemu VA et al. Sympathetic chemoreflex responses in obstructive sleep apnea and effects of continuous positive airway pressure therapy. Chest. 2007;131(5):1406–13.PubMedCrossRefGoogle Scholar
  18. 18.
    Fletcher EC. Invited review: physiological consequences of intermittent hypoxia: systemic blood pressure. J Appl Physiol. 2001;90(4):1600–5. 1985.PubMedGoogle Scholar
  19. 19.
    Rey S et al. Chronic intermittent hypoxia enhances cat chemosensory and ventilatory responses to hypoxia. J Physiol. 2004;560(Pt 2):577–86.PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Lai CJ et al. Enhanced sympathetic outflow and decreased baroreflex sensitivity are associated with intermittent hypoxia-induced systemic hypertension in conscious rats. J Appl Physiol. 2006;100(6):1974–82. 1985.PubMedCrossRefGoogle Scholar
  21. 21.
    Kuri BA et al. Increased secretory capacity of mouse adrenal chromaffin cells by chronic intermittent hypoxia: involvement of protein kinase C. J Physiol. 2007;584(Pt 1):313–9.PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    Czyzyk-Krzeska MF et al. Hypoxia increases rate of transcription and stability of tyrosine hydroxylase mRNA in pheochromocytoma (PC12) cells. J Biol Chem. 1994;269(1):760–4.PubMedGoogle Scholar
  23. 23.
    Evinger MJ et al. Hypoxia activates multiple transcriptional pathways in mouse pheochromocytoma cells. Ann N Y Acad Sci. 2002;971:61–5.PubMedCrossRefGoogle Scholar
  24. 24.
    Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol. 1992;12(12):5447–54.PubMedCentralPubMedGoogle Scholar
  25. 25.
    Keith B, Johnson RS, Simon MC. HIF1alpha and HIF2alpha: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer. 2012;12(1):9–22.Google Scholar
  26. 26.
    Yuan G et al. Hypoxia-inducible factor 1 mediates increased expression of NADPH oxidase-2 in response to intermittent hypoxia. J Cell Physiol. 2011;226(11):2925–33.PubMedCrossRefGoogle Scholar
  27. 27.
    Wykoff CC et al. The HIF pathway: implications for patterns of gene expression in cancer. Novartis Found Symp. 2001;240:212–25. discussion 225-31.PubMedCrossRefGoogle Scholar
  28. 28.
    Toledo RA et al. In vivo and in vitro oncogenic effects of HIF2A mutations in pheochromocytomas and paragangliomas. Endocr Relat Cancer. 2013;20(3):349–59.PubMedCrossRefGoogle Scholar
  29. 29.
    Brown ST, Reyes EP, Nurse CA. Chronic hypoxia upregulates adenosine 2a receptor expression in chromaffin cells via hypoxia inducible factor-2alpha: role in modulating secretion. Biochem Biophys Res Commun. 2011;412(3):466–72.PubMedCrossRefGoogle Scholar
  30. 30.•
    Pacak K et al. New syndrome of paraganglioma and somatostatinoma associated with polycythemia. J Clin Oncol. 2013;31(13):1690–8. First human syndrome linking HIF2A with increased synthesis and secretion of catecholamines.PubMedCentralPubMedCrossRefGoogle Scholar
  31. 31.
    Taieb D et al. First report of bilateral pheochromocytoma in the clinical spectrum of HIF2A-related polycythemia-paraganglioma syndrome. J Clin Endocrinol Metab. 2013;98(5):E908–13.PubMedCentralPubMedCrossRefGoogle Scholar
  32. 32.
    Lorenzo FR et al. A novel EPAS1/HIF2A germline mutation in a congenital polycythemia with paraganglioma. J Mol Med (Berl). 2013;91(4):507–12.CrossRefGoogle Scholar
  33. 33.
    Bartolomucci A et al. The extended granin family: structure, function, and biomedical implications. Endocr Rev. 2011;32(6):755–97.PubMedCentralPubMedCrossRefGoogle Scholar
  34. 34.
    O’Connor DT, Frigon RP. Chromogranin A, the major catecholamine storage vesicle soluble protein. Multiple size forms, subcellular storage, and regional distribution in chromaffin and nervous tissue elucidated by radioimmunoassay. J Biol Chem. 1984;259(5):3237–47.PubMedGoogle Scholar
  35. 35.
    Mahata SK et al. Novel autocrine feedback control of catecholamine release. A discrete chromogranin a fragment is a noncompetitive nicotinic cholinergic antagonist. J Clin Investig. 1997;100(6):1623–33.PubMedCentralPubMedCrossRefGoogle Scholar
  36. 36.
    Angelone T et al. The antihypertensive chromogranin a peptide catestatin acts as a novel endocrine/paracrine modulator of cardiac inotropism and lusitropism. Endocrinol. 2008;149(10): 4780–93Google Scholar
  37. 37.
    Hendy GN et al. Targeted ablation of the chromogranin A (ChgA) gene: normal neuroendocrine dense-core secretory granules and increased expression of other granins. Mol Endocrinol. 2006;20(8):1935–47.PubMedCrossRefGoogle Scholar
  38. 38.
    Mahapatra NR et al. Hypertension from targeted ablation of chromogranin A can be rescued by the human ortholog. J Clin Investig. 2005;115(7):1942–52.PubMedCentralPubMedCrossRefGoogle Scholar
  39. 39.
    O’Connor DT et al. Early decline in the catecholamine release-inhibitory peptide catestatin in humans at genetic risk of hypertension. J Hypertens. 2002;20(7):1335–45.PubMedCrossRefGoogle Scholar
  40. 40.
    Cotesta D et al. High plasma levels of human chromogranin A and adrenomedullin in patients with pheochromocytoma. Tumori. 2005;91(1):53–8.PubMedGoogle Scholar
  41. 41.
    Rao F et al. Catecholamine release-inhibitory peptide catestatin (chromogranin A(352-372)): naturally occurring amino acid variant Gly364Ser causes profound changes in human autonomic activity and alters risk for hypertension. Circulation. 2007;115(17):2271–81.PubMedCrossRefGoogle Scholar
  42. 41.••
    Tsigelny IF et al. Development of a pharmacophore model for the catecholamine release-inhibitory peptide catestatin: virtual screening and functional testing identify novel small molecule therapeutics of hypertension. Bioorg Med Chem. 2013;21(18):5855–69. This study showed abstract description of molecular features necessary for molecular recognition of catestatin leading to reduced blood pressure.PubMedCrossRefGoogle Scholar
  43. 43.
    Xu J et al. Renalase is a novel, soluble monoamine oxidase that regulates cardiac function and blood pressure. J Clin Investig. 2005;115(5):1275–80.PubMedCentralPubMedCrossRefGoogle Scholar
  44. 44.
    Li X et al. Renalase, a new secretory enzyme: its role in hypertensive-ischemic cardiovascular diseases. Med Sci Monit. 2014;20:688–92.PubMedCentralPubMedCrossRefGoogle Scholar
  45. 45.
    Gu R et al. Renalase deficiency in heart failure model of rats—a potential mechanism underlying circulating norepinephrine accumulation. PLoS ONE. 2011;6(1):e14633.PubMedCentralPubMedCrossRefGoogle Scholar
  46. 46.
    Zbroch E et al. Renalase, a novel enzyme involved in blood pressure regulation, is related to kidney function but not to blood pressure in hemodialysis patients. Kidney Blood Press Res. 2012;35(6):395–9.PubMedCrossRefGoogle Scholar
  47. 47.
    Wu Y et al. Renalase deficiency aggravates ischemic myocardial damage. Kidney Int. 2011;79(8):853–60.PubMedCrossRefGoogle Scholar
  48. 47.••
    Desir GV et al. Renalase lowers ambulatory blood pressure by metabolizing circulating adrenaline. J Am Heart Assoc. 2012;1(4):e002634. This study of renalase knockout mice showed success of recombinant renalase lowering blood pressure and plasma catecholamines.PubMedCentralPubMedCrossRefGoogle Scholar
  49. 49.
    Zhao Q et al. Renalase gene is a novel susceptibility gene for essential hypertension: a two-stage association study in northern Han Chinese population. J Mol Med (Berl). 2007;85(8):877–85.CrossRefGoogle Scholar
  50. 49.•
    Buraczynska M et al. Renalase gene polymorphisms in patients with type 2 diabetes, hypertension and stroke. Neuromolecular Med. 2011;13(4):321–7. Further reports of human renalase single nucleotide polymorphisms and its association with hypertension.PubMedCentralPubMedCrossRefGoogle Scholar
  51. 51.
    Baraka A, El Ghotny S. Cardioprotective effect of renalase in 5/6 nephrectomized rats. J Cardiovasc Pharmacol Ther. 2012;17(4):412–6.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Division of Endocrinology, Diabetes, and MetabolismUniversity of Rochester School of Medicine and DentistryRochesterUSA

Personalised recommendations